Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03648814 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 21, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Enrollment target: 70 to 40
    • Primary and study completion dates: Jul 1, 2023 to Jul 1, 2026
    v5
  2. Primary and study completion dates: Jul 1, 2022 to Jul 1, 2023v4
  3. Primary and study completion dates: Jul 1, 2021 to Jul 1, 2022v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.
Trial Details
NCT Number NCT03648814
Lead Sponsor Prince of Songkla University
Conditions
(from sponsor)		 Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression
Related terms Glaucoma, Neovascular
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov